# Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

Study · id `cardio:ct-nct04327232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04327232](<https://clinicaltrials.gov/study/NCT04327232>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04327232

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 184 participants.

## Technical summary

Registry record NCT04327232. Randomized; triple masking; primary purpose prevention. Start 2018-05-23 (actual); primary completion 2022-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 184 participants (planned count; ClinicalTrials.gov record NCT04327232, source copy `cardio:ctgov-nct04327232-2020-03-31`, retrieved 2026-10-26)
- Started: 2018-05-23 (actual) (ClinicalTrials.gov record NCT04327232, source copy `cardio:ctgov-nct04327232-2020-03-31`, retrieved 2026-10-26)
- Primary completion: 2022-05-31 (anticipated) (ClinicalTrials.gov record NCT04327232, source copy `cardio:ctgov-nct04327232-2020-03-31`, retrieved 2026-10-26)
- Completion: 2022-05-31 (anticipated) (ClinicalTrials.gov record NCT04327232, source copy `cardio:ctgov-nct04327232-2020-03-31`, retrieved 2026-10-26)
- Countries: Singapore (ClinicalTrials.gov record NCT04327232, source copy `cardio:ctgov-nct04327232-2020-03-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04327232-2020-03-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study
- Condition: Atrial Fibrillation
- Intervention (Drug): Spironolactone 25mg
- Intervention (Drug): Placebo oral tablet
- Lead sponsor: National University Hospital, Singapore
- Lead sponsor class: OTHER
- Collaborator: University of Otago
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: National University Hospital, Singapore (`cardio:org-national-university-hospital-singapore`)
- Registry lists this organization as a collaborator: University of Otago (`cardio:org-university-of-otago`)

## Provenance

Content hash: 943499e807feb2ea8c805271e42a022ed7c729c9b8b959044154fab4e4317e34
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
